股本结构
单位：万股
| 公告日期 | 2023-05-22 | 2023-05-22 | 2023-04-17 | 2023-04-17 | 2022-11-10 | 2022-11-10 |
|---|---|---|---|---|---|---|
| 证券总股本 | 320.15 | 320.15 | 320.15 | 320.14 | 306.39 | 302.14 |
| 普通股本 | 320.15 | 320.15 | 320.15 | 320.14 | 306.39 | 302.14 |
| 优先股 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 其他 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 变动日期 | 2023-04-30 | 2023-03-31 | 2023-02-28 | 2022-12-31 | 2022-10-31 | 2022-09-30 |
注释：中概股证券总股本=普通股股本/
存托凭证比例
，当前存托凭证比例为：1
历史变动
| 公告日期 | 变动后普通股本（万股） | 变动后优先股（万股） | 变动原因 | 变动日期 |
|---|---|---|---|---|
| 2023-05-22 | 320.15 | 未披露 | 定期报告 | 2023-04-30 |
| 2023-05-22 | 320.15 | 未披露 | 定期报告 | 2023-03-31 |
| 2023-04-17 | 320.15 | 未披露 | 定期报告 | 2023-02-28 |
| 2023-04-17 | 320.14 | 未披露 |
更多>>
From December 31, 2021 to December 31, 2022
Issuance of ordinary shares
Shares issued in connection with the vesting of restricted stock units
|
2022-12-31 |
| 2022-11-10 | 306.39 | 未披露 | 定期报告 | 2022-10-31 |
| 2022-11-10 | 302.14 | 未披露 |
更多>>
From June 30, 2022 to September 30, 2022
Issuance of ordinary shares
Shares issued in connection with the vesting of restricted stock units
|
2022-09-30 |
| 2022-09-15 | 280.00 | 未披露 |
更多>>
Nabriva Therapeutics plc announced that it will effect a 1-for-25 reverse stock split of its outstanding ordinary shares, which will be effective for trading purposes on the Nasdaq Capital Market as of the commencement of trading on September 16, 2022. The reverse stock split will reduce the number of ordinary shares outstanding from approximately 69.7 million to approximately 2.8 million post-split.
|
2022-09-16 |
| 2022-09-15 | 6970.00 | 未披露 | 定期报告 | 2022-09-15 |
| 2022-08-03 | 6654.47 | 未披露 | 定期报告 | 2022-07-31 |
| 2022-08-03 | 6458.02 | 未披露 |
更多>>
From March 31, 2022 to June 30, 2022
Issuance of ordinary shares
Shares issued in connection with the vesting of restricted share units
|
2022-06-30 |
| 2022-07-11 | 6433.35 | 未披露 | 定期报告 | 2022-06-24 |
| 2022-05-05 | 6320.48 | 未披露 | 定期报告 | 2022-04-30 |
| 2022-05-05 | 6172.52 | 未披露 |
更多>>
From January 1, 2022 to March 31, 2022
Issuance of ordinary shares
Shares issued in connection with the vesting of restricted share units
|
2022-03-31 |
| 2022-03-29 | 6119.77 | 未披露 | 定期报告 | 2022-03-28 |
| 2022-03-29 | 6052.54 | 未披露 | 定期报告 | 2022-02-28 |
| 2022-02-22 | 6038.47 | 未披露 | 定期报告 | 2022-02-18 |
| 2022-03-29 | 5671.53 | 未披露 |
更多>>
From December 31, 2020 to December 31, 2021
Issuance of ordinary shares
Shares issued in connection with the vesting of restricted stock units
Equity transaction costs
|
2021-12-31 |
| 2021-11-22 | 5671.97 | 未披露 | 定期报告 | 2021-11-19 |
| 2021-11-09 | 5431.66 | 未披露 | 定期报告 | 2021-10-31 |
| 2021-11-09 | 5431.55 | 未披露 |
更多>>
From June 30, 2021 to September 30, 2021
Issuance of ordinary shares
Shares issued in connection with the vesting of restricted stock units
Equity transaction costs
|
2021-09-30 |
| 2021-08-05 | 4973.89 | 未披露 | 定期报告 | 2021-07-31 |
| 2021-08-05 | 4973.76 | 未披露 |
更多>>
From March 31, 2021 to June 30, 2021
Issuance of ordinary shares
Shares issued in connection with the vesting of restricted stock units
|
2021-06-30 |
| 2021-07-01 | 4941.07 | 未披露 | 定期报告 | 2021-05-31 |
| 2021-05-06 | 3541.96 | 未披露 | 定期报告 | 2021-04-30 |
| 2021-05-06 | 3541.28 | 未披露 |
更多>>
From January 1, 2021 to March 31, 2021
Issuance of common stock
Shares issued in connection with the vesting of restricted share units
|
2021-03-31 |
| 2021-03-03 | 3538.57 | 未披露 |
更多>>
1.Ordinary shares offered by the company in this offering 9,761,010 ordinary shares.
2.The number of ordinary shares to be issued and outstanding after this offering is based on 25,024,653 ordinary shares issued and outstanding as of February 26, 2021.
|
2021-03-03 |
| 2021-03-01 | 2502.47 | 未披露 | 定期报告 | 2021-02-26 |
| 2021-03-11 | 2107.88 | 未披露 |
更多>>
from December 31,2019 to December 31,2020
Issuance of ordinary shares
Shares issued in connection with the employee stock purchase plan
Shares issued in connection with the vesting of restricted stock units
|
2020-12-31 |
| 2020-12-15 | 2107.88 | 未披露 |
更多>>
1.Securities offered by the company in this offering 6,000,000 ordinary shares.
2.The number of ordinary shares to be issued and outstanding after this offering is based on 15,078,781 ordinary shares issued and outstanding as of December 4, 2020.
|
2020-12-15 |
| 2020-12-10 | 1507.88 | 未披露 | 定期报告 | 2020-12-04 |
| 2020-12-03 | 1508.00 | 未披露 |
更多>>
On December 2, 2020 (the “Effective Date”), Nabriva Therapeutics plc (the “Company”) filed an Amended and Restated Memorandum and Articles of Association of the Company (the “Amended Articles of Association”) with the Irish Companies Registration Office and effected, as of 5:00 p.m. Eastern Standard Time on the Effective Date, a one-for-ten reverse stock split (the “Reverse Stock Split”) of the Company’s ordinary shares, nominal value $0.01 per share (the “Ordinary Shares”).
|
2020-12-03 |
| 2020-11-05 | 15077.57 | 未披露 | 定期报告 | 2020-10-31 |
| 2020-11-05 | 15000.64 | 未披露 |
更多>>
From June 30, 2020 to September 30, 2020
Issuance of ordinary shares
Shares issued in connection with the vesting of restricted stock units
|
2020-09-30 |
| 2020-09-01 | 14395.52 | 未披露 | 定期报告 | 2020-08-31 |
| 2020-09-01 | 14382.91 | 未披露 | 定期报告 | 2020-08-14 |
| 2020-08-06 | 14382.23 | 未披露 | 定期报告 | 2020-07-31 |
| 2020-08-06 | 14296.55 | 未披露 |
更多>>
from March 31, 2020 to June 30, 2020
Issuance of ordinary shares
Shares issued in connection with the employee stock purchase plan
Shares issued in connection with the vesting of restricted stock units
|
2020-06-30 |
| 2020-06-25 | 14296.55 | 未披露 | 定期报告 | 2020-06-05 |
| 2020-06-02 | 14295.87 | 未披露 |
更多>>
1.Ordinary shares offered by us 41,445,373 ordinary shares.
2.The number of ordinary shares to be issued and outstanding after this offering is based on 101,513,318 ordinary shares issued and outstanding as of May 15, 2020.
|
2020-06-02 |
| 2020-06-01 | 10151.33 | 未披露 | 定期报告 | 2020-05-15 |
| 2020-05-11 | 9997.28 | 未披露 | 定期报告 | 2020-04-30 |
| 2020-05-11 | 9510.90 | 未披露 |
更多>>
From January 1, 2020 to March 31, 2020
Issuance of common stock
Shares issued in connection with the vesting of restricted stock units
|
2020-03-31 |
| 2020-03-12 | 9462.36 | 未披露 | 定期报告 | 2020-02-28 |
| 2020-03-12 | 9454.51 | 未披露 |
更多>>
from December 31, 2018 to December 31, 2019
Issuance of ordinary shares and warrants
Shares issued in connection with the vesting of restricted stock units
Shares issued in connection with the employee stock purchase plan
Shares issued in connection with the acquisition of Zavante Therapeutics, Inc.
|
2019-12-31 |
| 2019-12-24 | 9454.51 | 未披露 |
更多>>
1.Ordinary shares offered by us 13,793,106 ordinary shares.
2.The number of ordinary shares to be issued and outstanding after this offering is based on 80,752,010 ordinary shares issued and outstanding as of December 16, 2019.
|
2019-12-24 |
| 2019-12-20 | 8075.20 | 未披露 | 定期报告 | 2019-12-16 |
| 2019-11-12 | 7835.05 | 未披露 | 定期报告 | 2019-10-31 |
| 2019-11-12 | 7799.42 | 未披露 |
更多>>
from June 30, 2019 to September 30, 2019
Issuance of ordinary shares
Shares issued in connection with the vesting of restricted stock units
Shares issued in connection with acquisition of Zavante Therapeutics, Inc.
|
2019-09-30 |
| 2019-08-08 | 7336.14 | 未披露 | 定期报告 | 2019-07-30 |
| 2019-08-08 | 7290.63 | 未披露 |
更多>>
From March 31, 2019 to June 30, 2019
Issuance of common stock
|
2019-06-30 |
| 2019-06-25 | 7278.25 | 未披露 | 定期报告 | 2019-05-31 |
| 2019-05-10 | 7255.73 | 未披露 | 定期报告 | 2019-04-30 |
| 2019-05-10 | 7133.60 | 未披露 |
更多>>
From January 1, 2019 to March 31, 2019
Issuance of common stock
|
2019-03-31 |
| 2019-03-12 | 6969.97 | 未披露 | 定期报告 | 2019-02-28 |
| 2019-03-12 | 6701.91 | 未披露 |
更多>>
from December 31, 2017 to December 31, 2018
Issuance of common stock
Shares issued in connection with the acquisition of Zavante Therapeutics, Inc.
|
2018-12-31 |
| 2018-11-06 | 6698.21 | 未披露 | 定期报告 | 2018-10-26 |
| 2018-11-06 | 6648.42 | 未披露 | 定期报告 | 2018-09-30 |
| 2018-08-09 | 6648.42 | 未披露 | 定期报告 | 2018-07-31 |
| 2018-08-09 | 4095.95 | 未披露 | 定期报告 | 2018-06-30 |
| 2018-06-19 | 4070.10 | 未披露 | 定期报告 | 2018-06-06 |
| 2018-06-19 | 4068.76 | 未披露 | 定期报告 | 2018-06-01 |
| 2018-05-08 | 4030.69 | 未披露 | 定期报告 | 2018-04-30 |
| 2018-05-08 | 4023.39 | 未披露 | 定期报告 | 2018-03-31 |
| 2018-03-16 | 3671.64 | 未披露 | 定期报告 | 2018-02-28 |
| 2018-03-16 | 3670.77 | 未披露 |
更多>>
from December 31, 2016 to December 31, 2017
Issuance of common stock
Exercise of stock options
Redomiciliation share exchange
|
2017-12-31 |
| 2017-11-09 | 3669.15 | 未披露 | 定期报告 | 2017-09-30 |
| 2017-08-21 | 2721.71 | 未披露 | 定期报告 | 2017-08-17 |
| 2017-07-28 | 2683.83 | 未披露 | 定期报告 | 2017-06-30 |
| 2017-05-10 | 272.11 | 未披露 | 定期报告 | 2017-03-31 |
| 2017-03-24 | 271.99 | 未披露 | 定期报告 | 2017-03-01 |
| 2017-03-24 | 271.97 | 未披露 |
更多>>
From December 31, 2015 to December 31, 2016
Issuance of common stock
Exercise of stock options
|
2016-12-31 |
| 2016-11-16 | 212.80 | 未披露 |
更多>>
from January 1, 2016 to September 30, 2016
Exercised options (SOP)
|
2016-09-30 |
| 2016-08-09 | 212.73 | 未披露 | 定期报告 | 2016-06-30 |
| 2016-05-10 | 212.05 | 未披露 | 定期报告 | 2016-03-31 |
| 2016-04-28 | 211.68 | 未披露 |
更多>>
from December 31, 2014 to December 29, 2015
Paid in capital
Conversion of convertible loans
Contribution of silent partnerships
Exercised options (Kreos)
Exercised options (SOP)
|
2015-12-29 |
| 2015-11-10 | 209.90 | 未披露 | 定期报告 | 2015-09-30 |
| 2015-09-21 | 198.11 | 未披露 | 定期报告 | 2015-09-18 |
| 2015-09-08 | 106.40 | 未披露 | 定期报告 | 2015-08-31 |
| 2015-09-17 | 105.49 | 未披露 | 定期报告 | 2015-06-30 |
From December 31, 2021 to December 31, 2022
Issuance of ordinary shares
Shares issued in connection with the vesting of restricted stock units
From June 30, 2022 to September 30, 2022
Issuance of ordinary shares
Shares issued in connection with the vesting of restricted stock units
Nabriva Therapeutics plc announced that it will effect a 1-for-25 reverse stock split of its outstanding ordinary shares, which will be effective for trading purposes on the Nasdaq Capital Market as of the commencement of trading on September 16, 2022. The reverse stock split will reduce the number of ordinary shares outstanding from approximately 69.7 million to approximately 2.8 million post-split.
From March 31, 2022 to June 30, 2022
Issuance of ordinary shares
Shares issued in connection with the vesting of restricted share units
From January 1, 2022 to March 31, 2022
Issuance of ordinary shares
Shares issued in connection with the vesting of restricted share units
From December 31, 2020 to December 31, 2021
Issuance of ordinary shares
Shares issued in connection with the vesting of restricted stock units
Equity transaction costs
From June 30, 2021 to September 30, 2021
Issuance of ordinary shares
Shares issued in connection with the vesting of restricted stock units
Equity transaction costs
From March 31, 2021 to June 30, 2021
Issuance of ordinary shares
Shares issued in connection with the vesting of restricted stock units
From January 1, 2021 to March 31, 2021
Issuance of common stock
Shares issued in connection with the vesting of restricted share units
1.Ordinary shares offered by the company in this offering 9,761,010 ordinary shares.
2.The number of ordinary shares to be issued and outstanding after this offering is based on 25,024,653 ordinary shares issued and outstanding as of February 26, 2021.
from December 31,2019 to December 31,2020
Issuance of ordinary shares
Shares issued in connection with the employee stock purchase plan
Shares issued in connection with the vesting of restricted stock units
1.Securities offered by the company in this offering 6,000,000 ordinary shares.
2.The number of ordinary shares to be issued and outstanding after this offering is based on 15,078,781 ordinary shares issued and outstanding as of December 4, 2020.
On December 2, 2020 (the “Effective Date”), Nabriva Therapeutics plc (the “Company”) filed an Amended and Restated Memorandum and Articles of Association of the Company (the “Amended Articles of Association”) with the Irish Companies Registration Office and effected, as of 5:00 p.m. Eastern Standard Time on the Effective Date, a one-for-ten reverse stock split (the “Reverse Stock Split”) of the Company’s ordinary shares, nominal value $0.01 per share (the “Ordinary Shares”).
From June 30, 2020 to September 30, 2020
Issuance of ordinary shares
Shares issued in connection with the vesting of restricted stock units
from March 31, 2020 to June 30, 2020
Issuance of ordinary shares
Shares issued in connection with the employee stock purchase plan
Shares issued in connection with the vesting of restricted stock units
1.Ordinary shares offered by us 41,445,373 ordinary shares.
2.The number of ordinary shares to be issued and outstanding after this offering is based on 101,513,318 ordinary shares issued and outstanding as of May 15, 2020.
From January 1, 2020 to March 31, 2020
Issuance of common stock
Shares issued in connection with the vesting of restricted stock units
from December 31, 2018 to December 31, 2019
Issuance of ordinary shares and warrants
Shares issued in connection with the vesting of restricted stock units
Shares issued in connection with the employee stock purchase plan
Shares issued in connection with the acquisition of Zavante Therapeutics, Inc.
1.Ordinary shares offered by us 13,793,106 ordinary shares.
2.The number of ordinary shares to be issued and outstanding after this offering is based on 80,752,010 ordinary shares issued and outstanding as of December 16, 2019.
from June 30, 2019 to September 30, 2019
Issuance of ordinary shares
Shares issued in connection with the vesting of restricted stock units
Shares issued in connection with acquisition of Zavante Therapeutics, Inc.
From March 31, 2019 to June 30, 2019
Issuance of common stock
From January 1, 2019 to March 31, 2019
Issuance of common stock
from December 31, 2017 to December 31, 2018
Issuance of common stock
Shares issued in connection with the acquisition of Zavante Therapeutics, Inc.
from December 31, 2016 to December 31, 2017
Issuance of common stock
Exercise of stock options
Redomiciliation share exchange
From December 31, 2015 to December 31, 2016
Issuance of common stock
Exercise of stock options
from January 1, 2016 to September 30, 2016
Exercised options (SOP)
from December 31, 2014 to December 29, 2015
Paid in capital
Conversion of convertible loans
Contribution of silent partnerships
Exercised options (Kreos)
Exercised options (SOP)